Drugs For Severe Hyperbilirubinemia Could Face Long Development Program
FDA’s Gastrointestinal Drugs Advisory Committee notes difficulty in identifying endpoint during a March 13 meeting to discuss potential drug development pathways for the disease.
You may also be interested in...
Whether the single pivotal trial provides ‘substantial and highly persuasive evidence of effectiveness’ is a key question for advisory committee, although FDA also seeks advice on adequacy of the data to characterize adverse neurodevelopment outcomes; if approved, the heme oxygenase inhibitor could face a restrictive Risk Evaluation and Mitigation Strategy.
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.
EMD Serono has been tracking Serostim packages since 2002; J&J is using Prezista 600 mg as a trial run for serialization.